30 filings · most recent first
RAPT 8-K Filings
Rapt Therapeutics Acquired By Glaxosmithkline In 175B Deal
Gsk Enters Agreement To Acquire Rapt Therapeutics For 22 Billion
Rapt Therapeutics To Present At 44Th Annual Jp Morgan Healthcare Conference
Rapt Therapeutics Cmo Departure And Consulting Agreement
Rapt Therapeutics Reports Third Quarter 2025 Financial Results And Clinical
Rapt Therapeutics Announces Underwritten Public Offering
Rapt Therapeutics Announces Positive Phase 2 Trial Results For Rpt904 In
Rapt Therapeutics Announces Exclusive License Agreement And Private Placement
Rapt Therapeutics Reports Q2 2025 Financial Results
Rapt Therapeutics Files Investor Presentation As Exhibit
Rapt Therapeutics Appoints Two New Directors To Its Board
Rapt Therapeutics Inc Announces 1For8 Reverse Stock Split
Rapt Therapeutics Files Investor Presentation Slides
Rapt Therapeutics Approves Equity Plans And Reverse Stock Split
Rapt Therapeutics Faces Nasdaq Delisting Risk Due To Low Share Price
Rapt Therapeutics Reports Improved Q1 2025 Financial Results
Rapt Therapeutics Announces Dr Wendye R Robbins Departure From Board
Rapt Therapeutics Reports Fourth Quarter 2024 Financial Results
Rapt Therapeutics Discloses Investor Presentation
Rapt Therapeutics Announces Key Board Changes
Rapt Therapeutics Licenses Antiige Monoclonal Antibody Jyb1904 From Jemincare
Rapt Therapeutics Reprices Underwater Stock Options For Key Executives
Rapt Therapeutics Reports Decreased Q3 Loss And Announces Workforce Reduction
Rapt Therapeutics Reports Second Quarter 2024 Financial Results
Rapt Therapeutics Announces Major Workforce Reduction
Rapt Therapeutics Inc Announces Voting Results From 2024 Annual Meeting
Rapt Therapeutics Announces First Quarter 2024 Financial Results
Rapt Therapeutics Announces Fourth Quarter 2023 Financial Results
Rapt Therapeutics Receives Fda Clinical Hold On Two Trials
Fda Places Clinical Hold On Rapt Therapeutics Trials For Zelnecirnon